S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Forecast, Price & News

$2.80
+0.10 (+3.70%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.67
$3.09
50-Day Range
$1.96
$2.80
52-Week Range
$1.86
$6.99
Volume
243,364 shs
Average Volume
109,771 shs
Market Capitalization
$89.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Lyra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
614.3% Upside
$20.00 Price Target
Short Interest
Healthy
0.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Lyra Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$13.38 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.78) to ($1.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

110th out of 983 stocks

Surgical & Medical Instruments Industry

11th out of 97 stocks


LYRA stock logo

About Lyra Therapeutics (NASDAQ:LYRA) Stock

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LYRA Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Lyra Therapeutics: Q1 Earnings Insights
BTIG Keeps Their Buy Rating on Lyra Therapeutics (LYRA)
See More Headlines

LYRA Price History

LYRA Company Calendar

Last Earnings
3/29/2023
Today
6/03/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYRA
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+614.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-55,280,000.00
Net Margins
-5,032.86%
Pretax Margin
-5,020.64%

Debt

Sales & Book Value

Annual Sales
$1.36 million
Book Value
$2.08 per share

Miscellaneous

Free Float
26,291,000
Market Cap
$89.15 million
Optionable
Not Optionable
Beta
-0.42

Key Executives

  • Dr. Maria Palasis Ph.D. (Age 58)
    CEO, Pres & Director
    Comp: $848.19k
  • Mr. Jason Cavalier (Age 50)
    CFO, Treasurer & Sec.
    Comp: $464.11k
  • Mr. R. Donald Elsey MBA (Age 69)
    Advisor
    Comp: $640.11k
  • Ms. Corinne Noyes (Age 55)
    Sr. VP of Commercial Strategy & Market Devel.
    Comp: $426.73k
  • Dr. Harlan W. Waksal M.D. (Age 70)
    Exec. Chairman
  • Dr. Carmichael S. Roberts Jr. (Age 54)
    Ph.D., Co-Founder
  • Mr. Ray Knox
    VP of Operations
  • Dr. Robert Richard Ph.D. (Age 66)
    Sr. VP of Technical Operations
  • Ms. Ellen Cavaleri
    Sr. VP of Investor Relations & Communications
  • Ms. Vineeta Belanger Ph.D.
    Sr. VP of Clinical Affairs













LYRA Stock - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings
or view top-rated stocks.

What is Lyra Therapeutics' stock price forecast for 2023?

1 analysts have issued twelve-month price targets for Lyra Therapeutics' stock. Their LYRA share price forecasts range from $20.00 to $20.00. On average, they expect the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts price targets for LYRA
or view top-rated stocks among Wall Street analysts.

How have LYRA shares performed in 2023?

Lyra Therapeutics' stock was trading at $3.14 at the start of the year. Since then, LYRA shares have decreased by 10.8% and is now trading at $2.80.
View the best growth stocks for 2023 here
.

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 17,700 shares, a drop of 31.4% from the April 30th total of 25,800 shares. Based on an average daily volume of 38,000 shares, the days-to-cover ratio is currently 0.5 days.
View Lyra Therapeutics' Short Interest
.

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our LYRA earnings forecast
.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.06. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.36 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 69.00% and a negative net margin of 5,032.86%.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an initial public offering (IPO) on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

What is Lyra Therapeutics' stock symbol?

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.15%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyra Therapeutics' stock price today?

One share of LYRA stock can currently be purchased for approximately $2.80.

How much money does Lyra Therapeutics make?

Lyra Therapeutics (NASDAQ:LYRA) has a market capitalization of $89.15 million and generates $1.36 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How can I contact Lyra Therapeutics?

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.lyratherapeutics.com. The company can be reached via phone at 617-393-4600 or via email at laurence@gilmartinir.com.

This page (NASDAQ:LYRA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -